RecoveryRx is the immune-restoration telehealth company built on Lodonal® — a precision low-dose naltrexone therapy — in clinical-development partnership with Biostax Corp. One molecule. Six pathways. Sixteen indications. Treating the chronic inflammation that drives Long COVID, autoimmune disease, chronic pain, PTSD, cancer-adjunctive care, and addiction recovery — together, not in silos.
RecoveryRx is the immune-restoration telehealth company built to treat the biological roots of chronic illness — not the symptoms a body produces once its signaling systems begin to fail.
We go beyond traditional telehealth. We deliver a unified clinical platform that restores immune function, alleviates chronic pain, supports mental health, and adapts to each patient in real time through intelligent digital monitoring.
Our care is built on Lodonal® — a patented, pharmaceutical-grade low-dose naltrexone immune modulator developed by our clinical-development partner, Attune Biotech Inc. (formerly Biostax Corporation). Lodonal acts on the upstream signaling pathways — TLR4, OGF–OGFr, glial activation, and the mitochondrial-immune axis — that drive Long COVID, autoimmune disease, chronic pain, post-traumatic stress, and the conditions of post-viral and post-treatment immune exhaustion.
Lodonal is paired with STARR, Attune Biotech's digital health companion platform — integrating AI-driven biometric monitoring, validated mental-health measurement, and evidence-based stress regulation tools field-validated in healthcare, military, and educational settings.
We do not treat isolated symptoms. We interrupt the self-perpetuating cycle that defines chronic disease: stress → inflammation → pain → immune dysfunction → mental-health decline.
Our approach combines biological precision, psychological insight, and digital engagement to restore health and resilience from the inside out.
Backed by federal partnerships, the active IND portfolio held by Attune Biotech, and a multidisciplinary clinical network licensed across all 50 states, RecoveryRx delivers scalable, non-addictive, biologically intelligent care to the high-need populations failed by fragmented chronic-care delivery — across Long COVID, HIV immune non-responders, chronic pain, PTSD, autoimmune disease, and beyond.
To restore human resilience by addressing the root causes of chronic illness — delivering integrated, non-suppressive therapies that heal the immune system, relieve suffering, and empower mental and physical recovery, at the scale and accessibility that modern telehealth enables.
To lead a global transformation in chronic-disease care through a unified delivery model that fuses precision immunotherapy with continuous digital monitoring — replacing the fragmented, symptom-suppressive, specialty-by-specialty status quo with biologically intelligent, person-centered care.
Naltrexone has been an FDA-approved opioid receptor antagonist since 1984. What changed everything was the discovery — by Dr. Bernard Bihari in the mid-1980s — that a fraction of the dose produces an entirely different, opposite effect: not blockade, but restoration.
Naltrexone is a competitive antagonist at the µ-, κ-, and δ-opioid receptors. At the standard 50–100 mg dose, it produces sustained 24-hour blockade — the basis for its use in alcohol and opioid use disorder, where blocking reward signaling extinguishes the drive to drink or use.
At low doses (1–5 mg), the math inverts. The receptor blockade lasts only 3–6 hours. During that brief window, the body senses the loss and compensates: production of endogenous opioid peptides — β-endorphin, met-enkephalin, opioid growth factor — surges. Receptors upregulate by 87%. When the naltrexone clears, the body's own healing chemistry finds an immune system newly primed to listen.
Beyond the opioid system, naltrexone is also a Toll-like receptor 4 (TLR4) antagonist. TLR4 is the brain's and gut's primary inflammatory alarm. When naltrexone binds it, microglial activation drops. IL-6, TNF-α, and nitric oxide production fall. Macrophage and T-lymphocyte activity calms. Regulatory T-cells expand. NK cells regain surveillance capacity. The immune system returns to something a healthy version of you would recognize.
Lodonal® is the standardized, GMP-manufactured, patent-protected pharmaceutical form of low-dose naltrexone — built to deliver this biology with the consistency that compounded LDN cannot.
More than 100 million Americans live with conditions rooted in immune dysregulation and chronic inflammation. Most are treated as if they are unrelated. They are not.
Chronic cytokine elevation (IL-6, TNF-α, CRP) crosses the blood-brain barrier, activates microglia, and produces brain fog, fatigue, and mood collapse — which themselves provoke more inflammation through stress, sleep loss, and metabolic disruption.
High-CRP patients show 70% SSRI resistance. PTSD and chronic pain activate identical neuroinflammatory pathways. Treating only the symptom guarantees the loop continues.
The only way out is to interrupt the loop at its biology.
Lodonal® is not an immunosuppressant. It is a precision immune modulator. It works through six complementary mechanisms — each validated in clinical trials, each pulling the body toward equilibrium.
Brief receptor blockade triggers a 43% rebound in β-endorphin. Multi-modal pain relief — non-addictive, no tolerance.
Suppresses the primary innate-immune alarm. Reduces IL-6, TNF-α, IL-1β, and CRP at the source — preserves host defense.
Calms activated microglia and astrocytes. Lifts brain fog, mood collapse, and central pain sensitization.
112% increase in cellular ATP. Complex I activity ↑142%. mtDNA copy number ↑140%. Genuine cellular energy recovery.
Increases regulatory T-cells by ~60%. NK and CD8+ surveillance up 50–70%. Immune system distinguishes self from threat.
Reduces danger-associated molecular patterns released by stressed tissue. Calms the chronic alarm that perpetuates the cycle.
Naltrexone is one of the rare drugs whose biology genuinely depends on the dose. Lodonal occupies the low-dose territory — where the molecule's anti-inflammatory and immune-modulating effects emerge — not the standard 50–100 mg used to extinguish opioid or alcohol reward.
The four tiers below summarize the clinical pharmacology of the broader naltrexone family, adapted from Toljan et al. (2018). Lodonal's six standardized GMP strengths span 0.05 mg through 5 mg — the full therapeutic window for immune restoration.
0.05 mg is the very-low-dose starter for highly sensitive populations (fibromyalgia, EDS / MCAS, post-viral, chronic Lyme). 1–5 mg spans the primary LDN therapeutic window across inflammatory, autoimmune, neuro-immune, metabolic, and oncology-adjunctive indications. Manufactured under U.S. cGMP at SPG Pharma / Aveva (FEI 783982093).
These are not isolated wins. They are the pattern of a body coming back online — observed across nearly 200 catalogued studies, spanning inflammatory, immune, neurologic, metabolic, behavioral, and functional domains.
Twenty-four biomarker signals across six categories, drawn from Phase 2 trials, VA and DoD real-world cohorts, FDA-validated endpoints, mechanistic studies, and international regulatory programs.
Treat the shared biology, and a dozen named diseases begin to move at once. This is not multi-indication theater. It is the consequence of treating cause, not category.
Where the immune system has lost the line between self and threat. Lodonal restores tolerance via Treg expansion and TLR4 modulation — without the broad immunosuppression that defines the standard of care.
Phase 2 RCT showed 88% achieved ≥70-pt CDAI decline vs 40% placebo. Endoscopic and histologic mucosal healing confirmed. Pediatric Crohn's: 67% achieved disease-activity improvement.
First-in-class steroid-sparing candidate. FDA Orphan Drug Designation. ALT/AST and IgG normalization observed without chronic corticosteroid burden — the standard unchanged for 50 years.
Norwegian study of 360 patients showed reduced DMARD and opioid use on LDN. Reduced disease activity (DAS28) correlated with inflammatory marker decline.
Penn State Hershey retrospective (n=215): 75% reported good-to-slight fatigue benefit, 52% MRI stability. Cree et al. RCT: significant Mental Health Composite improvement vs placebo.
Adjunct therapy for systemic lupus and Sjögren's — reduces fatigue, CRP, ESR, and pruritus. Steroid-sparing effects with preserved infection defense.
Reduces autoimmune attack on thyroid tissue. Monitor TSH/FT4 closely as patients on levothyroxine may need dose reduction. ↓ TPO antibodies in observational series.
Reduced PASI scores in psoriasis cohorts. Improved GI tolerance scores in systemic sclerosis. Effective post-biologic in hidradenitis suppurativa.
Where central sensitization has converted real injury into permanent alarm. Lodonal calms the microglia and restores endorphin tone — without the addiction, tolerance, or cognitive cost of opioids.
Marcus et al. observational (n=41): mean pain reduction of 5.15 points on Brief Pain Inventory (p<0.01). Improved mood and energy. Discontinuation rate <6%.
Glial-cell inhibition reduces central sensitization in CRPS. Shown effective for treatment-resistant cases where standard analgesics, sympathetic blocks, and ketamine have failed.
Neuropathic pain, post-surgical chronic pain, and treatment-resistant inflammatory pain. Multi-modal relief via β-endorphin reset + TLR4 antagonism. 67% reduction in opioid requirements observed.
Benign familial chronic pemphigus — a debilitating skin disease for which low-dose naltrexone has emerged as one of the few effective treatments. Off-label utilization documented.
Mast cell stabilization reduces histamine and tryptase release in EDS/MCAS cohorts. Particularly valuable where standard antihistamines and stabilizers fail. Start low, titrate slowly.
Mitochondrial restoration (ATP +112%, Complex I +142%) directly addresses the energy collapse defining ME/CFS. Functional improvements in 58% of patients across post-viral cohorts.
Where the immune system and the nervous system are the same system. Cytokines do not merely correlate with mood — they cause it.
DOD military trial: 82% sustained recovery vs 24% standard of care. Reduced startle response, improved sleep architecture, autonomic regulation, memory. Career progression +112%.
High-CRP patients show 70% SSRI resistance — depression that cannot be treated without addressing inflammation. Lodonal targets the root cause where antidepressants don't.
Anxiety arising from autonomic dysfunction, mitochondrial collapse, or post-viral inflammation responds where SSRIs do not. Particularly relevant in Long COVID and post-EBV cohorts.
Where infection resolved but inflammation never did. Long COVID, post-EBV, post-influenza, and HIV immune-non-responder syndromes share a single signature: persistent immune activation in the absence of acute threat.
FDA Emergency Use Authorization filed under IND 181314 + Fast Track. Military trial: cognitive function +94%, physical performance +92%, return-to-duty 82%, T-cell exhaustion ↓65%.
Patients on stable ART with persistent CD4+ <200. Lodonal restores CD4/CD8 ratios and reduces sCD14 chronic inflammation. Approved for HIV immune maintenance outside the U.S.
Persistent immune activation following viral illness — fatigue, cognitive symptoms, exercise intolerance — responds to the same restoration mechanisms validated in PASC.
Where chronic inflammation has made the liver and metabolism stop listening. The 10 mg and 35 mg Lodonal protocols address the advanced end of this spectrum.
Biostax Phase 2 program (IND 147347): ALT ↓18.3 U/L, MRI-PDFF ↓18% hepatic fat fraction, fibrosis stabilization. Mitochondrial markers (Complex I, NAD+/NADH, PGC-1α) restored.
Most common chronic liver disease. 30% prevalence in VA enrolled population. Lodonal addresses HOMA-IR insulin resistance, hepatic CRP, and inflammatory markers driving progression.
For the inflammatory phenotype of T2DM where insulin resistance is cytokine-driven. Klotho-FGF21 activation enhances insulin sensitivity through endogenous upregulation.
Lodonal does not replace cancer treatment. It restores the immune and mitochondrial substrate that conventional therapy depletes — and may directly inhibit growth via the OGF-OGFr axis.
Hematologic malignancy RCT (n=89, 5 mo): improved physical/social/role functioning, weight maintenance, reduced nausea and appetite loss. NK and CD8+ recovery without checkpoint conflict.
MD Anderson Cancer Center series demonstrated 80% response rate in refractory cancer pain, including treatment-related neuropathy. Synergistic with cisplatin (3-fold apoptosis increase).
87% increase in OGFr expression. 40–60% reduction in DNA synthesis in cancer cell lines. Long-term survival cases documented in HCC, glioblastoma, RCC, and pancreatic cancer with metastases.
Children carry the same biology, more sensitively. Pediatric protocols use weight-based dosing (0.1–0.5 mg/kg/day, max 5 mg) with slower titration.
Multiple RCTs and open-label studies. Reduced hyperactivity, irritability, self-mutilation, stereotypy. Improved social responsiveness and communication. Immune normalization (CD4/CD8 ratio).
Egypt pediatric study: reduced seizure frequency and EEG normalization at 1–3 mg/day as adjunct to standard anticonvulsants. Mechanism: TLR4 and microglial modulation.
Phase 2 pilot (n=12): PCDAI scores decreased 34.2 → 21.7 (p=0.005). 25% achieved remission with histologic healing. Steroid-sparing — critical for growing children.
The skin is an immune organ. Most chronic dermatologic disease is an inflammatory loop with a visible signature. Lodonal acts on the underlying biology — reducing scaling, pruritus, and lesion recurrence.
Reduced PASI scores, scaling, and pruritus in clinical reviews. Particularly relevant in psoriasis with comorbid metabolic or autoimmune disease where biologics carry infection risk.
Reduced nodule count and lesion recurrence. Effective in patients post-biologic therapy (TNF-α blockers) where treatment options have narrowed. Patient quality-of-life gains documented.
Mast cell stabilization reduces pruritus in atopic dermatitis. Stabilizes hair loss in lichen planopilaris and frontal fibrosing alopecia. Cutaneous lupus and dermatomyositis adjunct.
Lodonal does not replace medication-assisted treatment for active opioid or alcohol use disorder — that is the territory of standard (50 mg) naltrexone. Lodonal addresses the chronic inflammation and pain syndromes that perpetuate addiction risk.
For patients in stable buprenorphine or naltrexone-50mg recovery with chronic pain. Lodonal addresses the underlying inflammatory pain that drives relapse — without re-introducing opioid risk.
Standard 50 mg naltrexone treats the reward biology directly. Lodonal addresses inflammatory comorbidity (hepatic, neuro, GI) in patients in recovery — supporting durability.
VA real-world cohort (15K patients): 38% reduction in substance use disorders among treated veterans, 44% improvement in depression and anxiety, 52% improvement in veteran-specific QoL.
Recovery is not a symptom checklist. It is a biological, cognitive, and emotional restoration — that must be treated as one whole.
RecoveryRx delivers three things in one continuous loop: a precision-formulated therapy, an always-on AI behavioral and biological monitoring system, and a nationwide network of clinicians ready to escalate the moment the data turns.
A patented, FDA 505(b)(2)-pathway low-dose naltrexone formulation — pharmaceutical-grade where compounded LDN is variable, standardized where 100,000+ VA prescriptions are not. One oral capsule, taken nightly.
A 24/7 behavioral and physiological monitoring platform. Daily symptom check-ins, wearable integration, biomarker trend analysis — and a predictive layer that flags clinical or psychiatric deterioration 14–30 days before it becomes a crisis.
A nationwide multidisciplinary network — psychiatry, behavioral therapy, primary care — operating in lockstep with the AI's signals. When the data turns, a clinician is already on the way.
Low-dose naltrexone has one of the most extensive safety records of any off-label medicine in modern clinical use. Forty years of data, no hepatotoxicity at LDN doses, no immunosuppression, no addiction potential, and minimal drug interactions. That is the case for it. Here is the case against it.
Low-dose naltrexone has been studied since Bernard Bihari's discovery in 1985. The Lodonal evidence base draws on the entire field — and adds the Phase 2 outcomes, biomarker validation, and real-world cohorts generated under Attune's INDs.
"Within sixteen weeks, fatigue, cognition, and respiratory function had improved by more than 80%. Ninety-four percent returned to active duty."
Sustained recovery rates of 82%, against 24% under standard of care. Combat veterans returning to civilian function — and many to peer-support roles.
Sixty-eight percent maintained sobriety at 18 months, with 67% lower opioid requirements — pain control improving, not deteriorating, as doses came down.
RecoveryRx is purpose-built for direct-to-patient delivery. Oral therapy, excellent safety profile, telehealth-native, with the regulatory foundation partners need to move quickly and the clinical evidence to defend the call.
Differentiate from the field with a precision immune-restoration offering that addresses the chronic-disease populations driving the highest patient lifetime value.
The VA writes 100,000+ compounded LDN prescriptions annually with 20–40% batch-to-batch variability. Lodonal is the same mechanism, standardized — eliminating regulatory and quality risk while unlocking $18.6–38.9B in projected annual savings.
Chronic inflammatory illness is the cost driver employers cannot touch with traditional benefits. RecoveryRx engages the employee population at risk — first responders, healthcare workers, veterans on staff — with a non-addictive therapy and continuous monitoring.
A multi-pathway, single-molecule therapy with measurable biomarker and utilization shifts — built for the value-based-care era. Insurance reimbursement strategy advancing alongside Phase 2/3 data.
Whether you are a clinician, a system, a partner, or a patient — there is a way to start. Choose the door that fits, and a member of the RecoveryRx team will respond within one business day.